LST1 and nonpapillary renal cell carcinoma: Second, therapeutic potential: targeting LST1 or its downstream MHC-I pathway may both alleviate chronic inflammation in T2DM and reverse immune suppression in ccRCC, providing a unified therapeutic strategy.